Aldebaran Therapeutics develops precision ocular antisense oligonucleotide (ASO) therapeutics for severe blinding diseases, including inherited retinal disease and age-related macular degeneration. The company leverages human genetics and its proprietary AntiClastic™ ASO format to create medicines with improved potency and minimized off-target effects. This approach aims to accelerate the delivery of meaningful therapeutic solutions to patients with unmet ocular needs.
Funding
$800K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe blinding diseases like inherited retinal disease, age-related macular degeneration, and glaucoma lack effective treatments that precisely target the underlying genetic causes, resulting in limited therapeutic outcomes for patients. Current approaches may also have off-target effects and inflammatory responses, reducing their therapeutic index.
Solution
Aldebaran Therapeutics develops precision ocular antisense oligonucleotide (ASO) therapeutics to address severe blinding diseases by targeting their genetic roots. The company's next-generation AntiClastic ASO medicines utilize established building blocks for precise design and leverage proprietary structures to improve potency and promote targeted delivery of antisense to RNA. This approach optimizes engagement of RNaseH for precise excision, minimizes off-target interactions with unintended RNA targets, and mitigates inflammatory responses, potentially improving the therapeutic index. Aldebaran uses human iPSC and in vivo models to de-risk and accelerate therapeutics to the clinic.
Target Audience
The primary target audience includes patients suffering from inherited retinal disease, age-related macular degeneration, and glaucoma, as well as the ophthalmologists and retinal specialists treating these conditions.
Features
- AntiClastic ASO format for improved potency and targeted delivery
- Precise design using established building blocks of market-validated ASOs
- Optimized engagement of RNaseH for precise excision of target RNA
- Minimized off-target interactions with unintended RNA targets
- Reduced inflammatory response for improved therapeutic index
- Diversified portfolio of precision ocular ASOs
- Utilization of human iPSC and in vivo models for de-risking and acceleration